Marketing authorisation application
Colin Kerr
Published: Saturday, February 1, 2020
Aerie Pharmaceuticals has submitted the marketing authorisation application (MAA) for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% with the European Medicines Agency (EMA). Roclanda® is currently marketed in the US as Rocklatan®.
”As EMA review of the Roclanda® MAA begins, we will be completing and analysing our Mercury 3 study, which compares Roclanda®to the leading fixed-dose combination product in the EU,” said Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer at Aerie.
www.aeriepharma.com
Tags: aerie, industry
Latest Articles
Simulators Benefit Surgeons and Patients
Helping young surgeons build confidence and expertise.
How Many Surgeries Equal Surgical Proficiency?
Internet, labs, simulators, and assisting surgery all contribute.
Improving Clinical Management for nAMD and DME
Global survey data identify barriers and opportunities.
Are Postoperative Topical Antibiotic Drops Still Needed?
Cataract surgeons debate the benefits of intracameral cefuroxime prophylaxis.
Emerging Technology for Detecting Subclinical Keratoconus
Brillouin microscopy shows promise in clinical studies.
Knowing Iris Repair: Modified Trifold Technique
Part eight of our series covers the modified trifold technique for large iris defects.
It’s All About Biomechanics!
Increasing the pool of patients eligible for refractive surgery.
Uncovering More Safe and Quick Options
Different strategies, such as PresbyLASIK, can offer presbyopes good outcomes.
Topography-Guided PRK for Keratoconus
Improving visual acuity in patients with keratoconus.
Defining AMD Treatment Protocol
Treatments trending to fewer injections for better results.